Molecular mechanisms of Buqing granule for the treatment of diabetic retinopathy: Network pharmacology analysis and experimental validation

doi:10.4239/wjd.v15.i9.1942

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1375)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-10) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

764

Figures (1-10)

Tables (1-5)

Sum=967

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

160

Sum=237

Publishing Process of This Article

Item

Count

Browse

Download

Sum=115

Sep 15, 2024 (publication date) through Nov 6, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Sep 15, 2024; 15(9): 1942-1961
Published online Sep 15, 2024. doi: 10.4239/wjd.v15.i9.1942

Full Size Figure Download Figure

Figure 6 Serum biochemical analyses and ELISA tests. A: Effect of Buqing granule (BQKL) on total cholesterol and triglyceride levels in the serum of diabetic retinopathy (DR) rats; B: Effect of BQKL on superoxide dismutase, malondialdehyde, and glutathione peroxidase contents in the retina of DR rats; C: Effect of BQKL on oxidative stress in rat serum. The sequence from left to right represents the control group, the model group, the BQKL group and the Calcium dobesilate group. ^aP < 0.05, ^cP < 0.001. BQKL: Buqing granule; CaD: Calcium dobesilate.

Citation: Yang YF, Yuan L, Li XY, Liu Q, Jiang WJ, Jiao TQ, Li JQ, Ye MY, Niu Y, Nan Y. Molecular mechanisms of Buqing granule for the treatment of diabetic retinopathy: Network pharmacology analysis and experimental validation. World J Diabetes 2024; 15(9): 1942-1961
URL: https://www.wjgnet.com/1948-9358/full/v15/i9/1942.htm
DOI: https://dx.doi.org/10.4239/wjd.v15.i9.1942